Interactions between 3,4-methylenedioxymethamphetamine (MDMA or ’ecstasy’) and Δ9-tetrahydrocannabinol (THC or ‘marihuana’) in humans
Double-blind, randomised, placebo-controlled crossover study (n=16) in regular ecstasy and cannabis users assessing cardiovascular, cognitive and serotonergic effects of 100 mg oral MDMA, vapourised THC (4–6 mg) alone and combined.
Details
Double-blind, randomised, placebo-controlled crossover in 16 regular ecstasy and cannabis users evaluating acute interactions between 100 mg oral MDMA and vapourised THC (reported 4 mg and 6 mg doses) given alone and in combination.
Primary outcomes include cardiovascular measures (systolic/diastolic blood pressure, heart rate, core temperature) and repeated state measures of psychomotor performance, memory (n-back), sedation (reaction time, saccadic velocity) and subjective effects (Bond and Lader VAS, VAS Bowdle). Secondary measures include serum catecholamines, cortisol, prolactin and drug/metabolite levels; side effects monitored throughout.